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Abstract
Severe dengue was perceived as one clinical disease entity until the WHO 2009 classifica-
tion stratified it into severe vascular leakage, severe bleeding, and severe organ dysfunc-
tion. The objectives of this study were to investigate the potential use of severe dengue
categories as endpoints for intervention research. 271 patients with severe dengue among
1734 confirmed dengue patients were followed prospectively in this hospital-based observa-
tional study in Latin America and Asia. We compared the distribution of severe dengue cate-
gories according to gender and age (below/above 15y), and determined the relative
frequency and the overlap of severe dengue categories in the same patients. In a next step,
we extended the analysis to candidate moderate severity categories, based on recently sug-
gested definitions which were adapted for our purposes. Severe vascular leakage occurred
in 244 (90%), severe bleeding in 39 (14%), and severe organ dysfunction in 28 (10%) of 271
severe dengue patients. A higher frequency of severe leakage was seen in children or ado-
lescents (<15y) compared to adults. More than 80% of the severe leakage cases, and 30–
50% of the cases with severe bleeding or severe organ dysfunction, were defined as severe
on the basis of that feature alone. In 136 out of 213 patients with severe leakage alone, nei-
ther moderate bleeding manifestation nor hepatic involvement was recorded. On the other
hand, moderate leakage manifestations were detected in 4 out of 12 cases that were classi-
fied as severe based on bleeding alone. A major proportion of severe dengue patients exhib-
ited clinical manifestations of severe vascular leakage only, which may constitute a useful
endpoint for intervention research or pathophysiology studies. Severe bleeding and severe
organ manifestation were recorded less frequently and exhibited a higher degree of overlap
with severe leakage. Severe bleeding without leakage may be associated with individual
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Author summary
Severe dengue (DHF/DSS) was perceived as one clinical disease entity until the WHO
2009 classification defined three categories: severe vascular leakage, severe bleeding, and
severe organ dysfunction. Here we provide new insight about the discriminatory power
and the overlap or co-occurrence of the severe dengue categories. We also respond to the
need to validate standard clinical endpoints for severe dengue in well-characterized data
sets. In addition, we respond to the need for moderate disease endpoints, which are
recorded more frequently than the severe ones. Severe vascular leakage alone constitutes
the largest group among the severe dengue categories and may be useful as endpoint for
intervention or pathophysiology research. Other severe dengue categories as for example
severe bleeding can also sometimes occur alone–however, this might be associated with
the presence of comorbidities or individual predisposition and should be studied in more
detail. Moderate disease endpoints were suggested and explored here, but need to be fur-
ther investigated.
Introduction
Dengue is one of the most important mosquito-borne diseases to affect humans worldwide. It
is known to be present in 126 countries, where 2.5 billion people or 40% of the world’s popula-
tion are at risk [1], and an estimated 390 million infections occur annually, of which around
100 million are symptomatic [2].
The clinical spectrum ranges from mild febrile illness to severe and potentially life-threaten-
ing disease [3]. In accordance with the World Health Organization (WHO) 2009 dengue clas-
sification scheme [4], the severe end of the disease spectrum is defined as: i) severe vascular
leakage resulting either in dengue shock syndrome or in respiratory distress due to fluid accu-
mulation; ii) severe bleeding; and iii) severe organ dysfunction. These severe categories appear
to affect children and adults differently [5]; thus severe vascular leakage is typically observed
more frequently in children, and severe bleeding more frequently in adults [6]. However, the
extent to which these severity categories overlap in the same patients remains unclear. As the
geographical spread of dengue has increased globally, severe disease is now being reported in
populations of all ages and with varying immunological backgrounds, resulting in a diversifi-
cation of the clinical picture. At the same time, there is an urgent need for operationalisation
and standardisation of clinical endpoints for dengue research studies.
In a recent effort to define standard clinical endpoints for use in dengue intervention trials,
criteria for moderate disease severity as well as severe disease endpoints were suggested by an
expert group, using a structured Delphi consensus method. The authors conclude by saying
that the endpoints suggested should be validated, ideally using existing large prospective data-
sets [7].
Between 2006 and 2007 we performed a prospective multicentre observational study (the
DENCO acute febrile illness cohort study) that enrolled participants with suspected dengue in
7 countries across Asia and Latin America [8], resulting in one of the largest and best curated
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datasets currently available describing the severe end of the clinical spectrum in a substantial
number of hospitalised dengue patients. Results from this study provided evidence to support
the 2009 revision of the WHO dengue case classification based on clinical severity [8, 9]. The
objective of the analysis presented here was to respond to the need for validation of standard-
ized endpoints, and to investigate the potential of the severe dengue categories to represent dis-
tinct clinical endpoints for intervention or pathophysiology research in dengue. This also led
to further exploration of the candidate definitions for moderate severity, which were adapted
from the definitions recently suggested by the expert group [7], considering the availability of
the proposed criteria/laboratory information in the DENCO dataset.
Methods
Study design & patient population
In the observational DENCO cohort study a total of 2259 patients with a possible diagnosis of
dengue were enrolled at 11 hospitals across seven dengue endemic countries. Trained physi-
cians used a single comprehensive case report form to follow all study participants daily
throughout the evolution of their illness. Details of the study design, patient population, classi-
fication algorithms, clinical definitions and laboratory criteria for diagnosis of dengue have
been described elsewhere [8]. Ethical approval was obtained from the review boards of each
hospital where patients were enrolled and from the Ethics Review Committee of WHO, and
written consent was provided by each participant or a parent/guardian prior to study enrol-
ment. Clinical monitoring was carried out by WHO-trained monitors following ICH-GCP
guidelines.
A total of 1734/2259 (77%) patients enrolled in the study were confirmed as having dengue
in accordance with a pre-specified diagnostic algorithm [8]. Demographics of the confirmed
dengue patients are described in Table 1. Of these, 271 were classified as having severe dengue,
following the system subsequently adopted in the 2009 WHO classification and summarised
in Table 2 [4]; in total 244 patients were classified as severe by vascular leakage, 39 by severe
bleeding and 28 by severe organ dysfunction, with more than one severe category identified in
32 of the cases. We first concentrated on the overlap of the categories at the severe end of the
clinical spectrum. In a second step, we expanded the analysis of the overlap beyond severe
Table 1. Characteristics of study population.
Non-severe Dengue Severe Dengue
Age 13 (9–20) 12 (8–17)
Sex
Female
Male
668 (82%)
795 (86%)
142 (18%)
129 (14%)
Country
Brazil
Nicaragua
Venezuela
All Latin America
Malaysia
Philippines
Thailand
Vietnam
All Southeast Asia
32 (91%)
71 (72%)
91 (92%)
194 (83%)
116 (72%)
308 (81%)
137 (82%)
708 (89%)
1269 (85%)
3 (9%)
28 (28%)
8 (8%)
39 (17%)
45 (28%)
72 (19%)
30 (18%)
85 (11%)
232 (15%)
Numbers represent the frequency (%) for binary and categorical variables and the median (interquartile range) for
continuous variables.
https://doi.org/10.1371/journal.pntd.0008076.t001
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disease and included less severe measures of vascular leakage, bleeding, and organ dysfunction
in the severe patients, using the “moderate severity” definitions presented in Table 2, which
were adapted from the definitions recently suggested by Tomashek et al. [7]. The reason for
adapting the definitions was that this data set was collected before these definitions became
available and therefore did not include certain information as for example if local interven-
tions for bleeding (e.g. pressure package) or cross-matching for blood transfusion were carried
out.
Statistical analysis
The distribution and overlap of the three severe categories were analysed using frequency dis-
tributions (including 95% CI of proportions) and Venn diagrams, stratified by age group
(<15years vs.�15years), gender, and continent (Latin America vs. Asia).
To assess whether laboratory variables and clinical signs or symptoms differed between the
severe dengue categories we carried out linear discriminant analysis (LDA). We evaluated lin-
ear combinations of variables, defined by coefficients (loadings) that best distinguished
between the severe leakage and severe bleeding categories [9]. As the severe organ dysfunction
category was relatively small and at the same time more heterogeneous (comprising a liver and
a CNS subgroup) than the bleeding category we elected not to include this category in this
comparative analysis. The initial list of candidate variables included 21 clinical (binary) and 6
laboratory (continuous) variables (S1 Table). Most of these explanatory variables are binary,
but multivariate normality is not a requisite for LDA to perform well [10]. Variable selection
was based on the criteria of (i) at least 90% non-missing values, (ii)� 5% abnormal values, and
(iii) retaining only one of the variables with similar content (e.g. ‘liver enlarged by more than
2cm’ and ‘liver palpable’). Finally, 13 binary and two continuous candidate variables were cho-
sen, their values being taken from the day when the criteria for either severity category were
first met [11]. The binary variables selected were nausea, abdominal pain or tenderness, leth-
argy, liver enlargement by more than 2cm, skin flush, rash, oedema, clinical pleural effusion,
ascites, mucosal bleeding, skin bleeding, haematocrit 20% over the baseline, and thrombocyto-
penia below 100,000 cells/μl. Haematocrit increase and platelet count were also included as
continuous variables. For the baseline haematocrit we collated data from healthy individuals
stratified by continent, age, and sex as previously described [8]. We aimed to discriminate
Table 2. Severe Dengue (SD) according to the WHO 2009 dengue classification, and moderate dengue according to the definitions used for this analysis.
Severe Dengue (SD) Moderate dengue severity
Vascular leakage - Shock (DSS)
- Fluid accumulation with respiratory distress
- Serosal fluid accumulation�
Bleeding - As evaluated by clinician, leading to haemodynamic
instability��
- Mucosal bleeding (excluding uncomplicated haematuria���) without
haemodynamic instability
Organ
dysfunction
- Liver: AST or ALT� 1000 U/L
- CNS: Impaired consciousness
(coma scale < 15 [GCS] or < 5 [BCS])
- Liver: 400 U/L� ALT < 1000 U/L
� Serosal fluid accumulation was diagnosed either clinically or radiologically. Clinical fluid accumulation was defined as clinical pleural effusion or ascites on any day.
Radiologically detected fluid accumulation (assessed within 24 hours of defervescence) was defined as pleural effusion by CXR or serosal fluid collection on ultrasound;
see also Rosenberger et al., 2016 [33].
�� Bleeding cases experienced gastrointestinal, skin or mucosal bleeding (e.g. nose bleed / bleeding at venepuncture sites; often multiple sites), which was evaluated as
‘severe’ by the treating physician based on the concern that the bleeding lead to haemodynamic instability. In most cases, severe bleeding was followed by administration
of blood products.
��� Haematuria was defined either microscopically / dipstick test (�10 erythrocytes/μl), or as macroscopic haematuria.
https://doi.org/10.1371/journal.pntd.0008076.t002
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between the groups using the smallest number of explanatory variables. Therefore, we initially
included all the parameters listed above, subsequently proceeding to drop first those with neg-
ative adjusted R2 from the model, then, one by one, those with p values more than 0.05.
For the LDA, patients diagnosed as severe in more than one category were classified accord-
ing to the first severe category they reached during the evolution of the illness episode. For par-
ticipants who qualified for both the severe leakage and severe bleeding categories on the same
day we performed the analysis twice, once assigning them to severe vascular leakage, and again
assigning them to severe bleeding. All data were analysed using STATA versions 10 or higher
(STATA Corporation, College Station, Texas).
Results
Epidemiology of severe dengue
Among the 271 patients classified as severe, 184 were below 15 years of age (17% of all
patients < 15 years; 95% CI 15.1–19.7) while 87 were aged 15 or more (13% of all
patients� 15 years; 95% CI 10.5–15.7). The majority of the severe patients were enrolled in
Asia (N = 232; 86%) compared to Latin America (N = 39), but the relative proportion of severe
patients as well as the relative frequency of severe dengue categories did not differ between the
continents (Table 3).
We observed a trend towards higher frequency of severe disease in females, particularly in
Asian children, among whom 71/470 boys (15%; 95% CI 12.0–18.7) were diagnosed with
severe disease compared to 81/427 girls (19%; 95% CI 15.4–23.0). In Latin America, case
Table 3. Frequency of severe dengue categories comparing children (< 15 years) versus adults and Asia versus Latin America.
Overall Asia & Latin America Asia Latin America
< 15 years > = 15 years < 15 years > = 15 years < 15 years > = 15 years
Non-Severe 1463 (84.4%;
82.1–86.1)
878 (82.7%; 80.3–
84.9)
585 (87.1%; 84.3–
89.5)
745 (83.0%; 80.4–
85.5)
524 (86.8%; 83.8–
89.4)
133 (80.6%; 73.7–
86.3)
61 (89.7%; 79.9–
95.8)
Severe
Male�
Female�
271 (15.6%; 13.9–
17.4)
129 (14.0%; 11.8–
16.4)
142 (17.5%; 15.0–
20.3)
184 (17.3%; 15.1–
19.7)
88 (15.8%; 12.8–
19.1)
96 (19.1%; 15.7–
22.8)
87 (12.9%; 10.5–
15.7)
41 (11.2%; 8.2–
14.9)
46 (15.0%; 11.2–
19.5)
152 (17.0%; 14.5–
19.6)
71 (15.1%; 12.0–
18.7)
81 (19.0%; 15.4–
23.0)
80 (13.2%; 10.6–
16.2)
41 (12.5%; 9.1–
16.6)
39 (14.1%; 10.2–
18.7)
32 (19.4%; 13.7–
26.3)
17 (19.3%; 11.7–
29.1)
15 (19.5%; 11.3–
30.1)
7 (10.3%; 4.2–
20.1)
0
7 (24.1%; 10.3–
43.5)
Plasma Leakage��
Clinical shock���
Fluid accumulation with
respiratory distress���
244 (90.0%; 85.8–
93.3)
210 (77.5%; 72.0–
82.2)
79 (29.2%; 23.8–
35.0)
173 (94.0%; 89.6–
97.0)
147 (79.9%; 73.4–
85.4)
68 (37.0%; 30.0–
44.4)
71 (81.6%; 61.8–
81.5)
63 (72.4%; 61.8–
81.5)
11 (12.6%; 6.5–
21.5)
144 (94.7%; 89.9–
97.7)
120 (78.5%;
72.6–85.1)
55 (36.2%; 28.6–
44.4)
71 (88.8%; 79.7–
94.2)
63 (78.8%; 68.2.-
87.1)
11 (13.8%; 7.1–
23.3)
29 (90.1%; 75.0–
98.0)
27 (84.4%; 76.2–
94.7)
13 (40.6%; 23.7–
59.4)
0
0
0
Bleeding�� 39 (14.4%; 10.4–
19.1)
22 (12.0%; 7.6–
17.5)
17 (19.5%; 11.8–
28.4)
19 (12.5%; 7.7–
18.8)
13 (16.3%; 8.9–
26.2)
3 (9.4%; 19.8–
25.0)
4 (57.1%; 18.4–
90.1)
Organ Dysfunction�� 28 (10.3%; 7.0–
13.6)
24 (13.0%; 8.5–
18.8)
12 (13.8%; 7.3–
22.9)
12 (7.9%; 4.1–
13.4)
9 (11.3%; 5.3–
20.3)
4 (12.5%; 3.5–
29.0)
3 (42.9%; 9.9–
81.6)
Total 1734 1062 672 897 604 165 68
Numbers represent frequencies (%; 95% confidence interval).
Numbers in the severity categories include overlapping cases.
Numbers in bold indicate statistically significant differences between age groups (non-overlapping 95% CI).
� Percentages refer to the number of male / female patients for the respective category in the denominator.
�� Percentages refer to the overall number of severe patients in the denominator.
��� Percentages in the severe categories refer to the number of severe patients for the respective category in the denominator.
https://doi.org/10.1371/journal.pntd.0008076.t003
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numbers were smaller and no difference was observed between male and female children, but
all severe disease in adults was recorded in females (N = 7; 24% of all adult females in LA; 95%
CI 10.3–43.5) (Table 3).
Severe dengue categories
Severe vascular leakage occurred in 244 (90%), severe bleeding in 39 (14%), and severe organ
dysfunction in 28 (10%) of 271 severe dengue patients. The severe dengue categories were
associated with age; a higher frequency of vascular leakage was seen in children and a higher
frequency of severe bleeding in adults. Among 184 children with severe dengue, 173 (94%;
95%CI 89.6–97.0) were diagnosed with severe vascular leakage compared to 71/87 (82%; 95%
CI 61.8–81.5%) adults. In contrast, severe bleeding was observed in 17/87 adults (20%; 95% CI
11.8–28.4%) versus 22/184 (12%; 95% CI 7.6–17.5%) children (Table 3).
The majority of severe cases was classified as severe in only one category (239/271, 88%),
primarily represented by vascular leakage (Fig 1). The 239 patients who were diagnosed as
severe on the basis of one category alone were further investigated regarding the presence of
moderate severity in the other categories (Table 4).
Moderate severity categories
Among the 213 patients with severe leakage alone, mucosal bleeding as a candidate moderate
bleeding marker occurred in 72 (34%), while hepatic involvement with moderately elevated
ALT liver enzyme was observed in 7 patients (3%; 2 of 7 overlapping with mucosal bleeding)
(Table 4). Thus, in the remaining 136 patients classified as severe by vascular leakage alone
(64%), no moderate severity markers for bleeding or organ dysfunction were identified.
Fig 1. Overlap between severe vascular leakage, severe bleeding and severe organ dysfunction in 271 patients with severe dengue. (A) Overlap between severe
plasma leakage, severe bleeding and severe organ dysfunction; (B) Overlap of shock and fluid accumulation with respiratory distress in 244 patients with severe
vascular leakage.
https://doi.org/10.1371/journal.pntd.0008076.g001
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Twelve patients were classified as severe based on severe bleeding alone, most of them
young adults (median age 21 years, IQR 14.5–26.5) who experienced severe bleeding from the
nose or gastrointestinal tract, or at venepuncture sites. The majority received blood products.
In four of these cases moderate vascular leakage was detected (i.e. clinical or radiological fluid
accumulation without respiratory distress), and in another four patients the assessment was
incomplete, due to lack of radiological diagnostic information within the pre-specified time-
frame. Thus, four patients remain with severe bleeding, without any vascular leakage docu-
mented (S2 Table) as well as without any other moderate severity features (Table 4), while
two of the 12 patients (17%) had moderate liver involvement.
In the 14 patients with severe organ dysfunction alone (6 with severe liver involvement and
8 with impaired consciousness), the majority (12/14, 86%) also had evidence of other moderate
severity markers—10 had fluid accumulation, 4 had mucosal bleeding, among them 2 were
diagnosed with both fluid accumulation and mucosal bleeding (Table 4).
Association patterns between clinical and laboratory markers by severity
category
We used linear discriminant analysis (LDA) to describe association patterns between clinical
and laboratory markers, investigating the question whether severe categories can be distin-
guished by the profile of abnormalities. For this purpose, we concentrated on severe vascular
leakage and severe bleeding occurring on the same day. After excluding individuals with miss-
ing values, we performed linear discriminant analysis in 222 patients. Within this subgroup,
13 patients met the criteria for severe bleeding, 201 for severe vascular leakage, and 8 met the
criteria for both on the same day. Classifying these 8 individuals (with vascular leakage and
bleeding) together with severe bleeding (total 21 cases), the LDA yielded a single discriminant
function including the following explanatory variables: lethargy (loading 1.40); flush (-0.84);
rash (-0.68); mucosal bleeding (-2.26); and skin bleeding (-0.40). Lethargy therefore had a posi-
tive loading (associated with leakage) while the others were negative (associated with bleed-
ing). Twenty of the 21 individuals in the bleeding group (95%) and 155 of 201 individuals in
the leakage group (77%) were correctly classified (S1 Fig).
When the 8 individuals were instead classified with the severe leakage group (total 209
cases), the variables flush, rash, and mucosal bleeding remained in the final model, still with
negative loadings (associated with bleeding). Lethargy and skin bleeding on the other hand
were replaced by clinical pleural effusion, ascites and haematocrit (in percent), all three associ-
ated with leakage. This correctly classified 11/13 (85%) of the bleeding group, and 170/209
(81%) of the vascular leakage group.
Table 4. Presence of moderate disease severity in 239 severe dengue patients who qualified for severe disease in one clinical category only.
N Moderate severity N (%) No moderate severity
Serosal fluid accumulation� Mucosal bleeding� Liver
(ALT� 400 U/L)�
Vascular leakage only
Clinical shock�
Fluid accumulation with respiratory distress�
213
182
66
- 72 (33.8%)
62 (34.1%)
19 (28.8%)
7 (3.3%)
5 (2.7%)
2 (3.0%)
136 (63.8%)
117 (64.3%)
45 (68.2%)
Bleeding only 12 4 (33.3%) - 2 (16.7%) 4 (33.3%)��
Organ dysfunction only 14 10 (71.4%) 4 (28.6%) - 2 (14.3%)
� Numbers include overlapping cases.
�� 4 patients were unclassifiable for serosal fluid accumulation due to missing information, see S2 Table.
https://doi.org/10.1371/journal.pntd.0008076.t004
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Discussion
The data presented provide crucial insights regarding the relative frequency and overlap of the
three severe dengue categories, vascular leakage, bleeding, and organ dysfunction. In the field
of malaria research, a similar approach proved to be instrumental for the field when the over-
lap of clinical subgroups within the “severe malaria” umbrella was characterised, and prognos-
tic features for these subgroups were identified [12]. However, the focus of the current analysis
was to assess the potential utility of using severe and moderate dengue as endpoints for
research studies, rather than on identifying prognostic features of these entities. The case fatal-
ity rate of hospitalised dengue cases is usually very low, estimated at<1% in many settings [4],
but can be substantially higher if medical management is not appropriate [13]. Only 2 of 1734
confirmed dengue patients in this study died—both children with severe vascular leakage and
shock—precluding use of these data for evaluation of prognostic factors relating to survival.
We were primarily interested in identifying differences between the disease categories,
rather than trying to distinguish between severe and moderate disease in general. Previously,
statistical evidence for a distinct overall moderate severity group has not been corroborated
[8]. The moderate disease definitions per category used in this analysis (Table 2) were based
on previous work using this data [33], as well as on the endpoints suggested recently by an
expert working group [7]. However, some of the variables listed in their moderate disease end-
point definitions—e.g. need for local intervention for bleeding (e.g. pressure packing) or
‘crossmatch performed for potential blood transfusion’—were not available, even in this well-
characterized prospective research dataset, and therefore the definitions had to be adapted.
The relative frequency of severe dengue categories differed according to age group. In line
with previous reports, vascular leakage was significantly more frequently observed in children
while bleeding manifestations occurred more frequently in adults, although this was not statis-
tically significant [5, 6]. It has also been argued that dengue in the Americas differs from Asia
[14], although we did not find a clear difference with this dataset.
With regard to gender, we saw a trend towards more severe disease in females in Asia, albeit
not statistically significant, with this trend more pronounced in girls compared to adult
females. Similar findings have been reported previously [15, 16], including higher mortality in
girls in Asia, and have been attributed to differences in health seeking behaviour or potentially
also to underlying differences in physiological responses between the sexes [17]. In Latin
America, overall numbers were considerably smaller compared to Asia and the results should
be interpreted with caution. However, we could not detect a signal for more severe disease in
girls compared to boys in Latin America. Interestingly, among adults all 7 severe disease cases
were female–in these instances not due to severe vascular leakage, but related to bleeding and
organ dysfunction.
From a phenotypic point of view, more than 80% of the severe vascular leakage cases and
30–50% of the cases with severe bleeding or severe organ manifestations were classified as
severe based on defining features present in only one severity category. Thus, severe leakage
alone may constitute a useful endpoint for intervention research or pathophysiology studies.
Using linear discriminant analysis, we were able to show that the group of patients with severe
leakage could be distinguished, based on their clinical and laboratory profiles, from a second
group that included most of the severe bleeding cases.
In a minority of cases we saw severe bleeding without vascular leakage documented. The lit-
erature describing dengue cases with severe bleeding, but without evident vascular leakage, has
been summarized by Bandyopadhay et al. [18]. However, many of the existing reports were
based on retrospective data where leakage manifestations might have gone unnoticed. In
response to these reports investigators have suggested new terminology such as ‘DFB’ (DF
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with unusual bleeding in the Delhi outbreak of 1996) or ‘DF with haemorrhage’ [19]. The ter-
minology of ‘DF with unusual hemorrhage’ was included in the PAHO guidelines in 1994
[20]. More recently, a series of dengue cases presenting with intracranial haemorrhage, but
without evidence of severe leakage, were reported by Sam et al. [21].
In addition to thrombocytopenia, various derangements in haemostatic parameters have
been described in association with dengue, including endothelial activation with release of von
Willebrand-factor [22], moderate coagulation activation with formation of thrombin-anti-
thrombin complexes, D-dimers and decreased fibrinogen levels [23], reduced thrombin for-
mation and excessive fibrinolysis [24], possibly with plasminogen activation. Plasminogen has
been shown to be activated by dengue virus in vitro [25] and plasminogen cross-reactive anti-
bodies have been detected during infection [26, 27]. However, clinical bleeding manifestations
are generally thought not to reflect a primary consumptive coagulopathy [23, 28], except when
compounded by the effects of profound shock or secondary bacterial infection when true dis-
seminated intravascular coagulation and major haemorrhage may occur.
In a disease like dengue with a broad clinical spectrum, research to elucidate mechanistic
pathways underlying specific phenomena relies on careful characterisation of individual clini-
cal phenotypes. The extent to which the original WHO 1997 and the revised 2009 dengue clas-
sification systems facilitate pathophysiology research has been a matter of some debate [29,
30]. For example, it has been argued that the 2009 severe dengue entity represents a mix of
end-stage manifestations involving various clinical pathways and potentially including comor-
bidities and/or iatrogenic factors [31]. However, the majority of experts attending a consensus
meeting in Latin America felt that the 2009 WHO classification is helpful in identifying cases
of dengue correctly for pathophysiological research, although they also recommended ongoing
research to improve the sensitivity and specificity of the definitions.[32].
Possible limitations of the current study include the fact that some participating hospital
sites were paediatric institutions, which is one reason why age-stratified results are reported.
Additionally, due to the observational nature of the study, medical management was not stan-
dardized, but all participating hospitals were local centres of excellence specialising in treat-
ment of dengue patients using local protocols derived from the WHO management guidelines.
We also acknowledge that the analysis was not stratified by serotype and that the majority of
severe cases were diagnosed in Asia. However, the relative frequency of the severe categories
within the age groups was comparable between Asia and Latin America. Furthermore, our
results reflect the clinical epidemiology usually observed in dengue-endemic countries where
the majority of severe cases exhibit secondary immune responses.
Conclusions
With 271 severe dengue patients recruited under the same protocol, this observational cohort
study represents one of the largest prospective datasets currently available describing the severe
end of the clinical spectrum in hospitalised dengue patients. The majority of the severe dengue
cases in this study were classified as severe based on defining features in only one severe cate-
gory, primarily vascular leakage.
Our results suggest that severe vascular leakage without (severe) bleeding or organ manifes-
tations can be reliably distinguished and therefore may be useful in itself as an endpoint for
intervention research as well as for pathophysiology research.
In a minority of cases we saw severe bleeding without vascular leakage documented. If not
caused by the heterogenous quality of assessment, we believe that this might result from a pre-
disposition where dengue served as a trigger for bleeding complications. In this case, the bleed-
ing is unlikely to be the result of consumption coagulopathy or hyperfibrinolysis, but rather
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caused by the derangements in the context of vascular leakage. Therefore, severe bleeding
without leakage may constitute a pragmatic endpoint for intervention research—however,
does not necessarily imply the existence of a distinct pathophysiological mechanism.
Our results are of importance with regard to the need for validation of standardized clinical
endpoints for severe disease. Definitions for moderate disease severity have recently attracted
more attention. Here we defined moderate disease severity based on the available data in this
well-characterized study. In the future, this needs to be further refined for each of the catego-
ries to increase the granularity of severity assessment. On the other hand, higher granularity
goes with the need for more technical or comprehensive investigations, which might not be
available outside of the context of research studies.
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